Exact Mass: 606.4134576
Exact Mass Matches: 606.4134576
Found 382 metabolites which its exact mass value is equals to given mass value 606.4134576,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PA(10:0/19:0)
PA(10:0/19:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/19:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of nonadecylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(15:0/14:0)
PA(15:0/14:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/14:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of myristic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(21:0/8:0)
PA(21:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(21:0/8:0), in particular, consists of one chain of heneicosylic acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/21:0)
PA(8:0/21:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/21:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of heneicosylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(10:0/i-19:0)
PA(10:0/i-19:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/i-19:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of isononadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/a-21:0)
PA(8:0/a-21:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/a-21:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of anteisoheneicosanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/i-21:0)
PA(8:0/i-21:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/i-21:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of isoheneicosanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(a-13:0/i-16:0)
PA(a-13:0/i-16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(a-13:0/i-16:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(a-21:0/8:0)
PA(a-21:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(a-21:0/8:0), in particular, consists of one chain of anteisoheneicosanoic acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-12:0/a-17:0)
PA(i-12:0/a-17:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-12:0/a-17:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of anteisoheptadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-12:0/i-17:0)
PA(i-12:0/i-17:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-12:0/i-17:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isoheptadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-13:0/i-16:0)
PA(i-13:0/i-16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-13:0/i-16:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-14:0/a-15:0)
PA(i-14:0/a-15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-14:0/a-15:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of anteisopentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-14:0/i-15:0)
PA(i-14:0/i-15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-14:0/i-15:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of isopentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-21:0/8:0)
PA(i-21:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-21:0/8:0), in particular, consists of one chain of isoheneicosanoic acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
Tasidotin
DG(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0)
DG(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0/0:0)
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/12:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(12:0/0:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
DG(12:0/0:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0/12:0)
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0/12:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
DG(13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/13:0/0:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(13:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
DG(13:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/13:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
DG(13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/13:0/0:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(13:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
DG(13:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/13:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
DG(13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/13:0/0:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(13:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
DG(13:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/13:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(a-13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
DG(a-13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(a-13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-13:0/0:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(a-13:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
DG(a-13:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/a-13:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/a-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(a-13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
DG(a-13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(a-13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-13:0/0:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(a-13:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
DG(a-13:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/a-13:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/a-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(a-13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
DG(a-13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(a-13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-13:0/0:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(a-13:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
DG(a-13:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/a-13:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/a-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0)
DG(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0/0:0)
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-12:0/0:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
DG(i-12:0/0:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0/i-12:0)
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0/i-12:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
DG(i-13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-13:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-13:0/0:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-13:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
DG(i-13:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/i-13:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/i-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
DG(i-13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-13:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-13:0/0:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-13:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
DG(i-13:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/i-13:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/i-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
DG(i-13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-13:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-13:0/0:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-13:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
DG(i-13:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/i-13:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/i-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
[7-acetyloxy-4,6-di(butanoyloxy)-8-hydroxy-3a,5a,9-trimethyl-1-propan-2-yl-1,2,3,4,5,6,7,8,10a,10b-decahydrocyclohepta[e]inden-2-yl] butanoate
(24S)-24-ethyl-cholesta-7,22E-diene-5alpha,6beta-diol 3-O-beta-D-glucoside|recurvoside B
7alpha-acetoxy-21R?,23R?-epoxy-1alpha,24S?,25-trihydroxy-21alpha-ethoxy-4,4,8-trimethyl-cholesta-14-en-3-one|brujavanone N
(2alpha,3beta,18beta)-23-O-(trans-p-coumaroyl)-19(18?17)-abeo-28-norolean-12-ene-2,3,18-triol|leonurusoleanolide G
3-O-beta-D-glucopyranosyl-14-H-27-norolean-12-ene-3beta,28,29-triol
(22E,24S)-3beta,25-dihydroxy-15alpha-O-beta-D-glucopyranosyl-ergosta-7,22-dien-6-one|fomentarol D
3alpha-hydroxy-11alpha-(4-hydroxy-3-methoxy)benzoyloxybauer-1-one|ulmuestone
1alpha,7alpha-diacetoxy-17alpha-20S-21,24-epoxy-apotirucall-14-ene-3alpha,23R,24S,25-tetraol
21alpha-hydroxyserrat-14-en-3beta-yl p-dihydrocaffeate|Phlegmanol A
3-[(2R,3S,4R,6R)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-4-hydroxy-6-[(4E,6E,9Z)-3-hydroxy-8-(hydroxymethyl)-2,6,10,12-tetramethyloctadeca-4,6,9-trien-2-yl]pyran-2-one
(3R,6R)-6-((3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-diacetoxy-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptane-1,3-diyl diacetate
(3R,6R)-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-diacetoxy-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptane-1,3-diyl diacetate
Cucurbitacin C3
(S)-2-[[(1R,2R)-2-[[[3,5-Bis(tert-butyl)-2-hydroxyphenyl]methylene]amino]cyclohexyl]thioureido]-N-benzyl-N,3,3-trimethylbutanamide
DG(i-12:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0)
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-12:0/0:0)
DG(i-12:0/0:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
DG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/0:0/i-12:0)
2-[hydroxy-[(2R)-2-hydroxy-3-[(Z)-tetracos-15-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
(2S)-2-[(3S,9E,14S)-7,14-Dimethyl-11-methylidene-15-[(2R)-14-methylpentadecan-2-yl]-2,5,8,13-tetraoxo-1-oxa-4,7,12-triazacyclopentadec-9-en-3-yl]-2-hydroxyacetamide
(3R,6R)-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-diacetoxy-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptane-1,3-diyl diacetate
WURCS=2.0/1,1,0/[hx12xh_3-6_1*OCCOCCCCCCCCCCCCCCCCCC/6=O_2*OCCO_4*OCCO_5*OCCO]/1
2,3-dihydroxypropyl [3-[(15Z,18Z)-hexacosa-15,18-dienoxy]-2-hydroxypropyl] hydrogen phosphate
(1-Acetyloxy-3-phosphonooxypropan-2-yl) heptacosanoate
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) tricosanoate
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) pentacosanoate
(1-Nonanoyloxy-3-phosphonooxypropan-2-yl) icosanoate
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) docosanoate
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) henicosanoate
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) hexacosanoate
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) tetracosanoate
(1-Dodecanoyloxy-3-phosphonooxypropan-2-yl) heptadecanoate
(1-Phosphonooxy-3-tridecanoyloxypropan-2-yl) hexadecanoate
(1-Phosphonooxy-3-tetradecanoyloxypropan-2-yl) pentadecanoate
(1-Phosphonooxy-3-undecanoyloxypropan-2-yl) octadecanoate
[3-hydroxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(1-Decanoyloxy-3-phosphonooxypropan-2-yl) nonadecanoate
(3R,6R)-6-((3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-diacetoxy-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptane-1,3-diyl diacetate
[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] octadecanoate
[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] octadecanoate
[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
2-[hydroxy-[(2R)-2-hydroxy-3-[(E)-tetracos-15-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
[1-carboxy-3-[2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(E)-dec-4-enoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-hydroxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
[1-carboxy-3-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(E)-tridec-8-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] nonadecanoate
[1-carboxy-3-[3-[(E)-dec-4-enoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-hydroxypropan-2-yl] (7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoate
2-[[2-hexanoyloxy-3-[(Z)-octadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-decanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-[(Z)-hexadec-9-enoxy]-2-octanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-pentanoyloxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-heptanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
2-[hydroxy-[2-[(Z)-icos-11-enoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-hydroxy-3-[(Z)-tetracos-13-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-heptanoyloxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-octanoyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-nonanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-acetyloxy-2-[(Z)-henicos-11-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(Z)-octadec-9-enoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-propanoyloxypropoxy]propyl]-trimethylazanium
2-[[2-decanoyloxy-3-[(Z)-tetradec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-butanoyloxy-2-[(Z)-nonadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[(Z)-heptadec-9-enoyl]oxy-3-hexanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-nonanoyloxypropoxy]propyl]-trimethylazanium
2-[[2-[(Z)-hexadec-9-enoyl]oxy-3-octoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-[(Z)-tridec-9-enoxy]-2-undecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-[(Z)-henicos-11-enoxy]-2-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-nonoxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(Z)-tridec-9-enoyl]oxy-3-undecoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-decoxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-[(Z)-heptadec-9-enoxy]-2-heptanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-acetyloxy-3-[(Z)-docos-13-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-butanoyloxy-3-[(Z)-icos-11-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-[(Z)-nonadec-9-enoxy]-2-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-nonanoyloxy-3-[(Z)-pentadec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
1-pentadecanoyl-2-tetradecanoyl-glycero-3-phosphate
1-heptadecanoyl-2-lauroyl-sn-glycero-3-phosphate
A 1,2-diacyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl groups at postions 1 and 2 are specified as heptadecanoyl and lauroyl respectively.
1-tetradecanoyl-2-pentadecanoyl-glycero-3-phosphate
BisMePA(28:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
2-{[3,10-dihydroxy-9-(hydroxymethyl)-2,2,4a,6a,6b,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicen-4-yl]oxy}oxane-3,4,5-triol
(2s,3s)-2-{[(2s)-2-(dimethylamino)-4-methylpentanoyl]oxy}-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-methylpentanimidic acid
(1r,3ar,3br,5as,9ar,9bs,11as)-1-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
6-{6,18-dihydroxy-7,7,12,16-tetramethyl-14-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl}-2-methylheptan-3-one
(1r)-4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(4r)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15-heptaen-1,17-diyn-1-yl]-3,5,5-trimethylcyclohex-3-en-1-yl acetate
(2r,3r,4s,5s,6r)-2-{[(1r,3ar,5r,5ar,7s,9ar,9bs,11ar)-1-[(2r,3e,5r)-5-ethyl-6-methylhept-3-en-2-yl]-5,5a-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,5h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3z,5e,7r,8s,9s,11e,13e,15s,16r)-8-hydroxy-16-[(2s,3r,4s)-3-hydroxy-4-[(2r,5s,6r)-2-hydroxy-6-isopropyl-5-methyloxan-2-yl]pentan-2-yl]-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
(1s,2r,4as,4br,6ar,7r,8r,9r,10ar,10br)-1,8,9-trihydroxy-4',4',4a,4b,7,10a-hexamethyl-3,4,5,6,6a,8,9,10,10b,11-decahydro-1h-spiro[chrysene-2,1'-cyclopentan]-7-ylmethyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
2-{[2-(dimethylamino)-4-methylpentanoyl]oxy}-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-methylpentanimidic acid
(1r,3s,3ar,5as,7s,9ar,9br,11ar)-7-hydroxy-1-[(2r,3e,5s)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9a,11a-dimethyl-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one
19-hydroxy-3,7,7,11,16,20,20-heptamethylpentacyclo[13.8.0.0³,¹².0⁶,¹¹.0¹⁶,²¹]tricos-1(23)-en-8-yl 3-(3,4-dihydroxyphenyl)propanoate
(3r,4r,4ar,6as,6br,8ar,10s,12ar,12br,14bs)-4a-({[(2r,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-3,4,10-triol
(1r,2s,3ar,4s,5ar,6s,7s,8s,10as,10br)-7-(acetyloxy)-4,6-bis(butanoyloxy)-8-hydroxy-1-isopropyl-3a,5a,9-trimethyl-1h,2h,3h,4h,5h,6h,7h,8h,10ah,10bh-cyclohepta[e]inden-2-yl butanoate
(1s,2r,4ar,6as,8as,10r,12as,12bs,13r,14as,14br)-10-hydroxy-1,2,4a,6a,9,9,12a,14a-octamethyl-12-oxo-1,2,3,4,5,6,8,8a,10,11,12b,13,14,14b-tetradecahydropicen-13-yl 4-hydroxy-3-methoxybenzoate
(1s,3ar,3br,5as,7s,9ar,9br,11ar)-1-[(2s,5e)-2,7-dihydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
(5r)-5-[(11r)-11-hydroxy-11-[(2r,5r)-5-[(1r,4z)-1-hydroxytetradec-4-en-1-yl]oxolan-2-yl]-5-oxoundecyl]-3-(2-oxopropyl)oxolan-2-one
3-[(2r,3r,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-6-[(3s,4e,6e,8s)-8-[(1z,4r)-2,4-dimethyldec-1-en-1-yl]-3,9-dihydroxy-2,6-dimethylnona-4,6-dien-2-yl]-2-hydroxypyran-4-one
(2s,3s)-2-{[(2s)-2-(dimethylamino)-4-methylpentanoyl]oxy}-n-[(2s)-1-[(2r)-2-[(2r)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-methylpentanimidic acid
3-[(2s,3s,4r,6r)-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-6-[(4e,6e)-8-[(1z)-2,4-dimethyldec-1-en-1-yl]-3,9-dihydroxy-2,6-dimethylnona-4,6-dien-2-yl]-4-hydroxypyran-2-one
(2e,6e,10e,12r,14e)-12-hydroxy-17-[(1s,3s,6s)-6-hydroxy-2,2,6-trimethyl-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}cyclohexyl]-2,6,10,15-tetramethylheptadeca-2,6,10,14-tetraenal
(6r)-6-[(1r,3r,6s,8r,11s,12s,14s,15r,16r,18r)-6,18-dihydroxy-7,7,12,16-tetramethyl-14-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-2-methylheptan-3-one
(1s)-1-{[(2s)-1-[(2r)-2-[(2r)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}-2-methylpropyl (2s)-2-(dimethylamino)-4-methylpentanoate
10-hydroxy-1,2,4a,6a,9,9,12a,14a-octamethyl-12-oxo-1,2,3,4,5,6,8,8a,10,11,12b,13,14,14b-tetradecahydropicen-13-yl 4-hydroxy-3-methoxybenzoate
2-[15-(hexadecan-2-yl)-5,13-dihydroxy-7,14-dimethyl-11-methylidene-2,8-dioxo-1-oxa-4,7,12-triazacyclopentadeca-4,9,12-trien-3-yl]-2-hydroxyethanimidic acid
(5r)-5-[(11r)-11-hydroxy-11-[(2r,5r)-5-[(1r)-1-hydroxytetradec-4-en-1-yl]oxolan-2-yl]-5-oxoundecyl]-3-(2-oxopropyl)oxolan-2-one
8-hydroxy-16-[3-hydroxy-4-(2-hydroxy-6-isopropyl-5-methyloxan-2-yl)pentan-2-yl]-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
(6r)-6-[(1s,3s,6s,8r,11s,12s,14s,15r,16r,18r)-6,18-dihydroxy-7,7,12,16-tetramethyl-14-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-2-methylheptan-3-one
2-{2-[(2-{[1,2-dihydroxy-3-(methylamino)decylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-n,4-dimethylpentanamido}-3-(4-hydroxyphenyl)propanoic acid
4-[18-(4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15-heptaen-1,17-diyn-1-yl]-3,5,5-trimethylcyclohex-3-en-1-yl acetate
2-(2-{2-[(3-amino-1,2-dihydroxydecylidene)amino]-n,3-dimethylbutanamido}-n,4-dimethylpentanamido)-3-(4-hydroxyphenyl)propanoic acid
(1s,2r,4as,4br,6ar,7r,8r,9r,10ar,10br)-1,8,9-trihydroxy-4',4',4a,4b,7,10a-hexamethyl-3,4,5,6,6a,8,9,10,10b,11-decahydro-1h-spiro[chrysene-2,1'-cyclopentan]-7-ylmethyl 3-(4-hydroxyphenyl)prop-2-enoate
5,5',7,7'-tetramethyl-20-oxa-7,7'-diazaspiro[heptacyclo[13.6.1.1⁵,⁹.0¹,¹².0⁴,¹¹.0¹⁴,¹⁶.0¹⁶,²¹]tricosane-19,12'-hexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane]-4(11),12-diene
(3z,5z,7z,9z,11z,13s,14r,16r,18r,22s,24r,26r,27z,29s,30s)-14,16,18,20,22,24,26-heptahydroxy-30-isopropyl-13,29-dimethyl-1-oxacyclotriaconta-3,5,7,9,11,27-hexaen-2-one
(2s,3s,4s,5s,6r)-2-{[(6e,14e,18e)-10-hydroxy-2,6,10,15,19,23-hexamethyltetracosa-2,6,14,18,22-pentaen-11-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
7-hydroxy-1-(6-hydroxy-5,6-dimethylhept-3-en-2-yl)-9a,11a-dimethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one
2-[10,12-dihydroxy-14-(hydroxymethyl)-3,10-dimethyltricyclo[9.3.0.0³,⁷]tetradec-7-en-6-yl]propyl 2-[2-hydroxy-3,5-dimethyl-6-(3-oxopentan-2-yl)oxan-2-yl]propanoate
n-[(2r,3e)-4-[(9r,10r,14ar,16ar,17s,19s,20ar,20br)-17-(c-hydroxycarbonimidoyloxy)-19-methoxy-3,10,13,20b-tetramethyl-7-oxo-9h,10h,14ah,16ah,17h,18h,19h,20h,20ah-naphtho[2,1-h]oxacyclohexadecan-9-yl]pent-3-en-2-yl]ethanimidic acid
C36H50N2O6 (606.3668680000001)